The Food and Drug Administration approved Teva Pharmaceutical Industries Ltd.'s (Nasdaq: TEVA) generic version of AstraZeneca's (Nasdaq: AZN) asthma drug Pulmicort. Shares of Teva rose 93 cents to $43.12 while AstraZeneca stock plummeted $3.92 to $38.05.
